Chinese vaccine makers jump on news of key success in cancer treatment, CanSino leads
MRNA•Chinese vaccine and biotech shares surge
Hong Kong shares of CanSino Biologics 6185.HK soar as much as 71.4% to HK$40, their highest point since January 2, leading a rally in HK-listed Chinese vaccine makers.
Shanghai shares of the human vaccine producer 688185.SS jump 20% to their highest level since May 25.
Healthcare stocks surged in both China and Hong Kong after Moderna MRNA.O and Merck MRK.N on Wednesday announced a major success in a new field of cancer treatment that sent Moderna's shares surging as much as 160%, while Merck jumped 12%.
HK-listed Genscript Biotech Corp 1548.HK jumps nearly 20% to HK$35.22, the highest level since December 2021.
Sino Biopharmaceutical 1177.HK jumps as much as 21.2% to HK$5.805, the highest since May 12.
Akeso Inc 9926.HK, Innovent Biologics 1801.HK, WuXi Biologics 2269.HK are up between 3.1% and 5.7%.
Hong Kong's Hang Seng Innovative Drug Index .HSIDI surges 4.7%, Hang Seng Biotech Index HSBIO up 4.5%.
China's CSI Vaccine and Biotech Index .CSI931992 jumps 9.2%.
